DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Anti-vascular endothelial growth factor for myopic choroidal neovascularization.

Author(s): Ng DS, Kwok AK, Chan CW

Affiliation(s): Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong Department of Ophthalmology, Hong Kong Sanatorium and Hospital, Hong Kong.

Publication date & source: 2011-09-08, Clin Experiment Ophthalmol., [Epub ahead of print]

Myopic choroidal neovascularization is a vision-threatening complication in eyes with pathological myopia, which is particularly prevalent among young and middle aged Asians globally. To date, the Verteporfin in Photodynamic Therapy (VIP) study is the only randomized-controlled study in treatment of subfoveal myopic choroidal neovascularization. However, its long-term benefit is controversial. Recently, intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) have shown promising results. In the absence of randomized-controlled trial comparing the efficacy of anti-VEGF with photodynamic therapy (PDT) and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic choroidal neovascularization. Furthermore, the influences of various doses and frequencies, as well as age and previous PDT treatment on its effect are described. (c) 2011 The Authors. Journal compilation (c) 2011 Royal Australian and New Zealand College of Ophthalmologists.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017